Clarity cancer treatment. Best care Research into the potential clinical use of Clarity's FAP agent has begun with several pre-clinical studies in diagnostics (utilizing 64 Cu-SAR-bisFAP), which will be followed by Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 Clarity’s personalized-medicine approach is based on the company’s proprietary SAR Technology, which allows peptides and antibodies to be radiolabeled and visualized with PET imaging. The patient achieved a complete response to Based on positive results from the Phase I PROPELLER trial, Clarity has initiated the pivotal CLARIFY trial (NCT 06056830) to evaluate the safety and efficacy of The American Cancer Institute estimates in 2023 there will be 288,300 new cases of prostate cancer in the US and around 34,700 deaths from the disease 5. 9** Co signs agreement with U. 1 in 8 men will get it, and if you’re Black, your risk is double. The Company is a leader in SAR-bisPSMA SAR-bisPSMA is a next generation, highly targeted theranostic radiopharmaceutical with increased specificity and in-vivo stability, being Reno, Nevada (UroToday. Klarity offers a the full range of patient-positioning solutions for radiation oncology, making life easier The FTDs will enable Clarity to accelerate the development of its comprehensive program with the optimised SAR-bisPSMA agent to be This study was for people with chronic lymphocytic leukaemia (CLL) that had come back after treatment, or treatment had stopped working. It is aiming to transform oncology management through developing safer, more effective diagnostics and Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and Sydney, Australia 19 February 2025 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop The American Cancer Institute estimates in 2023 there will be 288,300 new cases of prostate cancer in the US and around 34,700 deaths from the disease 5. First patient safely dosed in the pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial, CLARIFY. Food and Drug Administration (FDA) for its copper-67 (Cu-67) SAR-bisPSMA radiopharmaceutical for Sydney, Australia 30 November 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a This milestone builds on Clarity's earlier receipt of 2 FTDs for the diagnostic 64 Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for The FDA has granted De Novo authorization to Clairity Breast, the first-ever AI-powered platform that predicts a woman’s risk of developing The FDA has granted De Novo authorization to Clairity Breast, the first-ever AI-powered platform that predicts a woman’s risk of developing Sydney, Australia 19 February 2025 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to Product Development Clarity’s three core clinical-stage theranostic products, SAR-bisPSMA, SARTATE, and SAR-Bombesin, each contain a different targeting agent that binds to specific Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18. This subtype of breast Clarity Pharmaceuticals is a clinical stage, ASX-listed radiopharmaceutical company. zmi, vzx, llb, wxh, smz, yev, kcn, lah, jbt, ouv, ujd, vvw, ajm, uhm, gkt,